1 Min Read
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination with Yervoy (ipilimumab), by the Scottish Medicines Consortium (SMC) for the treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer (mCRC). Colorectal cancer is one of the most commonly diagnosed cancers in […] The post BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer appeared first on Pharmafile.
Work & Theory on February 6, 2026
Uncategorized